Assessment of quality o life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment
- Author(s)
- Yongsik Jung; Soo Jung Lee; Juneyoung Lee; Woo Chul Noh; Seok Jin Nam; Byeong-Woo Park; Young Tae Bae; Sung-Soo Kang; Heung Kyu Park; Jung-Han Yoon; Je Ryong Kim; Se Hun Cho; Lee Su Kim; Sung Hoo Jung; Chol Wan Lim; Sung Yong Kim; Ho Yong Park; Jeongyoon Song; Kwang Man Lee; Sung Hwan Park; Joon Jeong; Hae Lin Park; Sung Won Kim; Beom Seok Kwak; Sun Hee Kang; Young Up Cho; Geum Hee Gwak; Yong Lae Park; Sang Wook Kim; Sehwan Han; Byung In Moon
- Keimyung Author(s)
- Kang, Sun Hee
- Department
- Dept. of Surgery (외과학)
- Journal Title
- Journal of Breast Cancer
- Issued Date
- 2018
- Volume
- 21
- Issue
- 2
- Keyword
- Breast neoplasms; Letrozole; Quality of life; Treatment
- Abstract
- Purpose: There are few reports from Asian countries about the
long-term results of aromatase inhibitor adjuvant treatment for
breast cancer. This observational study aimed to evaluate the
long-term effects of letrozole in postmenopausal Korean women
with operable breast cancer. Methods: Self-reported quality of life
(QoL) scores were serially assessed for 3 years during adjuvant
letrozole treatment using the Korean version of the Functional
Assessment of Cancer Therapy-Breast questionnaires (version 3).
Changes in bone mineral density (BMD) and serum cholesterol
levels were also examined. Results: All 897 patients received the
documented informed consent form and completed a baseline
questionnaire before treatment. Adjuvant chemotherapy was
administered to 684 (76.3%) subjects, and 410 (45.7%) and 396
(44.1%) patients had stage I and II breast cancer, respectively.
Each patient completed questionnaires at 3, 6, 12, 18, 24, 30,
and 36 months after enrollment. Of 897 patients, 749 (83.5%)
completed the study. The dropout rate was 16.5%. The serial trial
outcome index, the sum of the physical and functional wellbeing
subscales, increased gradually and significantly from
baseline during letrozole treatment (p<0.001). The mean serum
cholesterol level increased significantly from 199 to 205 after 36
months (p=0.042). The mean BMD significantly decreased from
–0.39 at baseline to –0.87 after 36 months (p<0.001). Conclusion:
QoL gradually improved during letrozole treatment. BMD and
serum cholesterol level changes were similar to those in Western
countries, indicating that adjuvant letrozole treatment is well tolerated
in Korean women, with minimal ethnic variation.
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.